Famotidine and Antacids for Treatment of Dyspepsia

Part of paid clinical trials in Stony Brook, New York.

Sponsor
Stony Brook University
Study ID
NCT06241183
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Acid Reflux
  • Dyspepsia
  • GERD

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Intravenous Famotidine — DRUG
    Patients in this group will receive 20mg IV Famotidine.
  • Oral Maalox/ Mylanta — DRUG
    Patients in this group will receive 30 ml Maalox/ Mylanta.

Study Details

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

Key Dates

Start date
Nov 9, 2023
Status verified
Jun 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Intravenous Famotidine
    Patients in this group will receive 20 mg of intravenous famotidine.
  • Active Comparator: Oral Maalox
    Patients in the group will receive 30 ml of oral Maalox/ Mylanta.

Primary Outcome Measure

Verbal Numerical Pain Score [ Time Frame: at 1 hour ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stony Brook University HospitalStony BrookNew York11794
Andrea Gowie
Adam Singer, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Stony Brook, NY

By research site
Stony Brook University Hospital· Stony Brook, NY

Related Studies